GL Biochem declines, for the 8th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Vendors
Page 5 of 48 of this archive, newest first.
PeptideMeter result on a Suzhou liraglutide lot lands 4.0 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Janoshik result on a Zhuhai tirzepatide lot lands 2.5 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Independent analysis puts a FGP exenatide lot at 95.8%, against 93.2% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What changed at TFC in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Guangzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A supplier suspends shipping to Italy after 15 consecutive customs detentions
The route did not close because of a rule about peptides.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
QYB declines, for the 22nd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
From vial to bench: what is recorded and what is assumed
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
What a 7% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
PeptideMeter result on a Guangzhou orforglipron lot lands 1.7 points below the supplier’s figure
The supplier has not disputed the finding. It has not explained the gap either.
What changed at TFC in March, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at GL Biochem in March, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a GL Biochem liraglutide lot at 98.5%, against 94.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
What a 31% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What a 17% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.